Xiangpeng Kong

Title: Innovations of Xiangpeng Kong in Immunogenic Polypeptides

Introduction

Xiangpeng Kong is a notable inventor based in New York, NY (US). He has made significant contributions to the field of immunogenic polypeptides, holding a total of 2 patents. His work focuses on developing innovative solutions for vaccine compositions and immune responses against various pathogens.

Latest Patents

Kong's latest patents include groundbreaking inventions related to isolated immunogenic polypeptides. One patent describes a scaffold polypeptide that directs self-assembly to form a trimeric structure, which constrains epitopes to a conformation similar to native pathogen epitopes. This innovation is crucial for binding antibodies that react to these epitopes. Another patent involves an isolated immunogenic peptide derived from the V2 loop of the HIV-1 surface envelope glycoprotein gp120. This peptide specifically binds with antibodies in vaccinated patients, providing a potential pathway for eliciting anti-HIV-1 antibodies and protecting against infection.

Career Highlights

Throughout his career, Xiangpeng Kong has worked with prestigious institutions such as New York University and Molsoft LLC. His research has significantly advanced the understanding of immunogenic responses and vaccine development.

Collaborations

Kong has collaborated with esteemed colleagues, including Susan Zolla-Pazner and Maxim Totrov. These partnerships have further enriched his research and contributions to the field.

Conclusion

Xiangpeng Kong's innovative work in immunogenic polypeptides showcases his dedication to advancing medical science and vaccine development. His patents reflect a commitment to creating effective solutions for combating infectious diseases.